Metastatic Castration-resistant Prostate Cancer Clinical Trial
— CABA-DOCOfficial title:
A Study of Patient Preference Between Cabazitaxel and Docetaxel in First-line Chemotherapy for Metastatic Castrate-resistant Prostate Cancer
Verified date | August 2017 |
Source | Gustave Roussy, Cancer Campus, Grand Paris |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Taxotere is the current standard first-line chemotherapy for mCRPC and may be used as
second-line therapy in good responders in first-line (Taxotere rechallenge). Jevtana has
demonstrated a survival benefit versus mitoxantrone in patients progressing during or after
Taxotere and is now the standard second-line chemotherapy. Taxotere and Jevtana have
different toxicity profiles.
Many patients who are receiving Jevtana for second-line treatment indicate they prefer this
agent over Taxotere with regards to the general tolerance (namely peripheral neuropathy, nail
changes, asthenia). This was not expected since Jevtana in post-Taxotere setting was
associated with more grade 3-4 adverse events such as febrile neutropenia and diarrhea than
Taxotere in first-line setting.
The study design of CABA-DOC is similar to that of the PISCES trial which evaluated the
patient preference between two standard treatments for first-line metastatic kidney cancer.
Despite similar PFS improvements over placebo in phase III trials, results clearly showed
that patients preferred pazopanib over sunitinib.
A randomized phase III study is currently comparing the efficacy of Taxotere and Jevtana in
first-line setting with overall survival as a primary end-point. Assessing patient preference
between Jevtana and Taxotere would contribute to further identify differences between these
two taxanes and clarify which one of these two taxanes should be used for second-line
chemotherapy and perhaps for first-line chemotherapy in the future.
Assessing patient preference between the two taxanes might be less biased in the first-line
setting where patients have no previous experience with a taxane.
Status | Active, not recruiting |
Enrollment | 195 |
Est. completion date | April 2018 |
Est. primary completion date | April 13, 2017 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Affiliated to a social security regimen ; - Male patients older than 18 years ; - Histologically confirmed adenocarcinoma of the prostate ; - Continued androgen deprivation therapy either by LHRH agonists/antagonists or orchidectomy ; - Serum testosterone <0.50 ng/ml (1.7 nmol/L) ; - Progressive disease (PSA progression or radiological progression or clinical progression) ; - ECOG 0-2 ; - Information delivered to patient and informed consent form signed by the patient or his legal representative ; - Adequate organ or bone marrow function as evidenced by: - Hemoglobin >/= 10 g/dL - Absolute neutrophil count >/=1.5 x 109/L, - Platelet count >/=100 x 109/L, - AST/SGOT and/or ALT/SGPT </=1.5 x ULN; - Total bilirubin </=1.5 x ULN, - Serum creatinine </=1.5 x ULN. If creatinine 1.0 - 1.5 xULN, creatinine clearance will be calculated according to CKD-EPI formula and patients with creatinine clearance <60 mL/min should be excluded Exclusion Criteria: - Patients having received an investigational drug and/or prior surgery, radiation, chemotherapy, or other anti-cancer therapy within 4 weeks prior enrolment in the study, excepted radiotherapy directed to a single bone lesions which is nonacceptable if within 2 weeks ; - Prior treatment with Taxotere or Jevtana ; - Pre-existing symptomatic peripheral neuropathy grade > 2 (CTCAE V4) ; - Uncontrolled cardiac arrhythmias, angina pectoris, and/or hypertension. History of congestive heart failure (NYHA III or IV) or myocardial infarction within last 6 months is also not allowed ; - History of severe hypersensitivity reaction (grade =3) to polysorbate 80 containing drugs ; - Uncontrolled severe illness or medical condition (including uncontrolled diabetes mellitus), active infection including HIV infection, active Hepatitis B or C infection that would preclude participation in the trial ; - Concurrent or planned treatment with strong inhibitors or strong inducers of cytochrome P450 3A4/5 (a one week wash-out period is necessary for patients who are already on these treatments) ; |
Country | Name | City | State |
---|---|---|---|
France | Gustave Roussy | Villejuif | Val de Marne |
Lead Sponsor | Collaborator |
---|---|
Gustave Roussy, Cancer Campus, Grand Paris | Sanofi |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Patient preference | Patient preference (Taxotere versus Jevtana) assessed by a single question after completion of the second period of chemotherapy. Primary outcome measure will be assessed in the intent-to-treat population as defined by all patients having completed the first 4 cycles without progression and having received at least 1 cycle of the second treatment period. Patients having progressed during the first period will discontinue the trial. |
Assessed up 21 weeks after randomization |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04986423 -
ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Terminated |
NCT05489991 -
A Study of TmPSMA-02 Chimeric Antigen Receptor (CAR) T-cells in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05521412 -
EValuation of radIOLigand Treatment in mEn With Metastatic Castration-resistant Prostate Cancer With [161Tb]Tb-PSMA-I&T
|
Phase 1/Phase 2 | |
Terminated |
NCT04556617 -
PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
|
Phase 1/Phase 2 | |
Completed |
NCT02125357 -
Sequencing Abiraterone and Enzalutamide in mCRPC
|
Phase 2 | |
Recruiting |
NCT05917470 -
A Clinical Study of ONCT-534 in Subjects With Metastatic Castration-resistant Prostate Cancer.
|
Phase 1/Phase 2 | |
Recruiting |
NCT06052306 -
A Study to Learn How Safe the Study Treatment Actinium-225-macropa-pelgifatamab (BAY3546828) is, How it Affects the Body, How it Moves Into, Through and Out of the Body, and About Its Anticancer Activity in Men With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)
|
Phase 1 | |
Recruiting |
NCT05519449 -
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
|
Phase 1 | |
Terminated |
NCT05301062 -
A Research Called CREDIT Studies How Safe the Study Treatment Radium-223 is and How Well it Works in Chinese Men With Advanced Prostate Cancer That Has Spread to the Bones and Does Not Respond to Treatments for Lowering Testosterone Levels
|
||
Recruiting |
NCT05383079 -
Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men With Metastatic Castration-Resistant Prostate Cancer
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04060394 -
Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC
|
Phase 1/Phase 2 | |
Completed |
NCT01942837 -
Study of Enzalutamide in Patients With Castration-resistant Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05458544 -
[Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application
|
Phase 1/Phase 2 | |
Withdrawn |
NCT04879589 -
Phase 1 Study of ATRS-2002 in Healthy Male Adults
|
Phase 1 | |
Recruiting |
NCT03230734 -
Sequencing of Radium-223 and Docetaxel in Symptomatic Bone-only Metastatic Castration-resistant Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05116579 -
Circulating Tumor DNA (ctDNA) Monitoring in the Assessment and Prediction of the Efficacy of PARP Inhibitors (PARPi)
|
||
Active, not recruiting |
NCT03732820 -
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer
|
Phase 3 | |
Recruiting |
NCT05005728 -
XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05762536 -
Docetaxel or Cabazitaxel With or Without Darolutamide in mCRPC
|
Phase 2 |